|
|
|
Insider
Information: |
Morrison Briggs |
Relationship: |
Director |
City: |
Waltham |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
92,071 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$1,376,805 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
92,071 |
|
|
Total
Value |
$1,376,805 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
7
|
Stock
price went up :
|
2
|
4
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
2.0
|
1.3
|
Percentage
Gain/Loss : |
52.4%
|
-14.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
34,836 |
|
0 |
Premium* |
|
Arvinas Holding Company, Llc |
ARVN |
Director |
2022-04-14 |
19,976 |
|
0 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
Director |
2020-06-23 |
4,800 |
2020-06-23 |
0 |
Premium* |
|
Codiak Biosciences, Inc. |
CDAK |
Director |
2021-02-17 |
4,761 |
2021-02-17 |
0 |
Premium* |
|
Werewolf Therapeutics, Inc. |
HOWL |
Director |
2021-04-29 |
15,523 |
|
0 |
Premium* |
|
Carisma Therapeutics Inc |
CARM |
Director |
2023-03-07 |
12,175 |
2023-03-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
57 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CDAK |
Codiak Biosciences, Inc. |
Director |
|
2021-02-17 |
4 |
B |
$21.00 |
$99,981 |
D/D |
4,761 |
4,761 |
2.39 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2020-06-23 |
4 |
B |
$20.00 |
$96,000 |
D/D |
4,800 |
4,800 |
2.39 |
- |
|
CARM |
Carisma Therapeutics Inc |
Director |
|
2023-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,175 |
12,175 |
0 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2019-05-09 |
4 |
B |
$7.56 |
$99,726 |
D/D |
13,200 |
13,200 |
0.01 |
- |
|
HOWL |
Werewolf Therapeutics, In... |
Director |
|
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,523 |
|
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-04-01 |
4 |
AS |
$17.44 |
$1,763,515 |
D/D |
(101,045) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-04-04 |
4 |
AS |
$18.29 |
$57,220 |
D/D |
(3,128) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-07-01 |
4 |
AS |
$19.00 |
$1,183,430 |
D/D |
(62,292) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-14 |
4 |
AS |
$23.80 |
$2,085,855 |
D/D |
(87,645) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-15 |
4 |
AS |
$24.20 |
$1,616,035 |
D/D |
(66,775) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-16 |
4 |
AS |
$23.22 |
$2,902,438 |
D/D |
(125,000) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-19 |
4 |
AS |
$23.03 |
$2,633,044 |
D/D |
(114,339) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-09-20 |
4 |
AS |
$23.25 |
$1,387,012 |
D/D |
(59,649) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2023-02-06 |
4 |
AS |
$26.83 |
$1,417,909 |
D/D |
(52,854) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2023-03-13 |
4 |
AS |
$22.53 |
$1,190,674 |
D/D |
(52,854) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-04-10 |
4 |
S |
$19.53 |
$1,032,237 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-05-09 |
4 |
S |
$21.41 |
$1,131,478 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-06-09 |
4 |
S |
$21.18 |
$1,119,421 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-07-10 |
4 |
S |
$20.40 |
$1,078,068 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
|
|
2023-08-09 |
4 |
S |
$18.27 |
$965,402 |
D/D |
(52,855) |
17,836 |
0 |
% |
|
ARVN |
Arvinas Holding Company, ... |
Director |
|
2022-04-14 |
4 |
AS |
$65.24 |
$1,392,616 |
D/D |
(20,960) |
19,976 |
0 |
% |
|
SNDX |
Syndax Pharmaceuticals In... |
Chief Executive Officer |
|
2019-05-13 |
4 |
B |
$7.29 |
$52,517 |
D/D |
7,200 |
20,400 |
0.01 |
- |
|
SNDX |
Syndax Pharmaceuticals In... |
President, Head of R&D |
|
2022-04-04 |
4 |
OE |
$10.90 |
$34,095 |
D/D |
3,128 |
20,964 |
0 |
- |
|
ARVN |
Arvinas Holding Company, ... |
Director |
|
2022-01-14 |
4 |
AS |
$64.33 |
$1,374,021 |
D/D |
(20,960) |
24,748 |
0 |
% |
|
ARVN |
Arvinas Holding Company, ... |
Director |
|
2020-03-24 |
4 |
B |
$38.18 |
$95,450 |
D/D |
2,500 |
29,520 |
2.39 |
% |
|
57 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|